Algeria Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Algeria Breast Cancer Therapeutics Market Analysis

$ 3999

Increasing investments in healthcare infrastructure and the introduction of novel immunotherapeutic drugs in Algeria are responsible for the growth of Algeria's breast cancer therapeutics market from $36 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Laboratoire Beker, Hydrapharm, and Bristol-Myers Squibb are some of the key players in Algeria's breast cancer therapeutics market.

ID: IN10DZPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Algeria AUTHOR: Parul Choudhary

Buy Now

Algeria Breast Cancer Therapeutics Market Executive Analysis

The Algeria breast cancer therapeutics market size is at around $36 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Algeria's health statistics have improved as a result of a growing portion of the state budget—5.2% of GDP—being allocated to the health sector. The population has continued to receive benefits from the free public healthcare and social security program thanks to the government's allocation of $28 Bn during the last ten years, including $3 Bn in the 2020 state budget. Algeria is faced with a number of difficulties, such as widening healthcare access disparities and rising economic and social vulnerabilities. The public health system is plagued by inadequate administration, low service quality, disarray, and excessive bureaucracy despite significant spending. The sanitary crisis exposed systemic flaws and prompted the government to continue with numerous changes to modernize the health sector.

According to cancer file statistics, breast cancer has remained the most common malignancy in this demographic of women for the past three years, afflicting 30 out of every 100,000 women annually with a frequency of 36.1%. Breast cancer deaths have been reported in large numbers, mostly as a result of inadequate screening techniques that cause delayed diagnoses. By creating mobile mammography that may help cover the entire majority of Algerian land, especially the rural areas that are sparsely scattered in this largest country in Africa, efforts have been made to increase the screening rates.

Two immunotherapy medications (Pembrolizumab and Nivolumab) were registered in Algeria at the beginning of 2018 after showing encouraging results in a number of advanced cancer types, which has increased hopes for both physicians and patients. However, immunotherapy is linked to immunologically based side effects, the presence of which should allow for consideration of treatment adjustment, suspension, or even complete discontinuation. Therefore, only skilled and experienced oncologists should recommend these medicines to eligible patients.

Market Dynamics

Market Growth Drivers

The National Cancer Plan (NCP) of Algeria has made progress in terms of cancer treatment infrastructures (41 services and 77 chemotherapy units nationwide) and healthcare facilities (53 radiation accelerators, including 10 in the private sector) which will drive the Algeria breast cancer therapeutics market. The market will grow even more as a result of recent significant pharmaceutical spending in Algeria and the release of novel immunotherapy medications.

Market Restraints

Given the resources already allocated to the fight against cancer, it is not possible to finance immunotherapy for the benefit of all eligible patients without cutting back on wasteful spending in Algeria. Furthermore, the exorbitant prices that patients must bear for breast cancer treatment by immunotherapy will impede the Algeria breast cancer therapeutics market expansion.

Competitive Landscape

Key Players

Biopharm (DZA)
Merinal (DZA)
Laboratoire Beker (DZA)
Hydrapharm (DZA)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Either the Caisse Nationale de la Securite Sociale des Travailleurs Salaries (CNAS), which ensures salaried employees and their dependents, or a separate program, which ensures independent contractors and their dependents, provide health insurance to Algerian citizens. Both funds provide coverage for healthcare delivered in state-run hospitals or through the transfer abroad program, while in some circumstances insurance arrangements may be arranged between CNAS and private treatment facilities. In Algeria, the private healthcare industry is supported by the public healthcare system, but it is currently diversifying and adding services that are not offered by the public system. Due to the fact that few Algerians can afford to pay out-of-pocket for healthcare in the private healthcare sector and that their services are often not covered by the national health insurance plan, access to private medical care is still highly limited.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.